ORGO Q4 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$127M+27.1% YoY

Gross Profit

$96M75.5% margin

Operating Income

$10M8.1% margin

Net Income

$8M6.1% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$8M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$498M

Total Liabilities

$113M

Stockholders' Equity

$385M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$127M	$100M	+27.1%
Gross Profit	$96M	$72M	+33.0%
Operating Income	$10M	-$1M	+905.3%
Net Income	$8M	-$568,000	+1450.9%

Revenue Segments

Advanced Wound care

$242M94%

Surgical and Sports Medicine

$15M6%